Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Role of Receptor-interacting serine-threonine protein kinase 2 (RIPK2) in Insulin Resistance and Inflammation

EF 2013-14

Résumé
Obesity causes metabolic diseases, such as type 2 diabetes. More than half of the Canadian population are obese or overweight and this epidemic continues to grow at an alarming rate. This places an increasingly massive burden, not only on the health status of the individual, but also on the limited resources, medical professionals and financial state of our public healthcare system. There is a lot of emerging evidence for obesity acting on the immune system in type 2 diabetes. In a classical sense, your immune system serves to protect you, and is activated by harmful things in your environment or in your body, such as bacteria, viruses, or cancer cells. When the immune system is activated, it produces a temporary inflammatory response that helps to purge your body of the harmful organism or substance. Obese individuals have chronic, low-level inflammation and this factor causes pre-diabetes. We are searching for ways to stop obesity-induced inflammation. Previous work from our lab has shown that deletion of certain immune proteins can inhibit chronic activation of the immune system during obesity in mice. This reduces inflammation and hence, decreases pre-diabetes. You cannot just delete genes to fight human disease. Hence, we searched for drugs that can be used to inhibit this immune response. We found that the 2 cancer drugs, Iressa and Tarceva, which are currently being used in humans as a chemotherapy treatment, block the immune pathway we know is important in pre-diabetes. This research is targeted at re-tasking these drugs to reduce the chronic inflammation typically observed during obesity, in order to to combat pre-diabetes. We hope to develop a way to stop Type 2 Diabetes in overweight and obese individuals and reduce costs on the Canadian healthcare system.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311742
Name
Duggan Brittany
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Role of Receptor-interacting serine-threonine protein kinase 2 (RIPK2) in Insulin Resistance and Inflammation
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bacterial &Amp; Metabolic Stress; Diabetes; Endocrinology; Inflammation; Insulin Resistance; Metabolism; Obesity; Pattern Recognition Receptors
Abstract
Obesity causes metabolic diseases, such as type 2 diabetes. More than half of the Canadian population are obese or overweight and this epidemic continues to grow at an alarming rate. This places an increasingly massive burden, not only on the health status of the individual, but also on the limited resources, medical professionals and financial state of our public healthcare system. There is a lot of emerging evidence for obesity acting on the immune system in type 2 diabetes. In a classical sense, your immune system serves to protect you, and is activated by harmful things in your environment or in your body, such as bacteria, viruses, or cancer cells. When the immune system is activated, it produces a temporary inflammatory response that helps to purge your body of the harmful organism or substance. Obese individuals have chronic, low-level inflammation and this factor causes pre-diabetes. We are searching for ways to stop obesity-induced inflammation. Previous work from our lab has shown that deletion of certain immune proteins can inhibit chronic activation of the immune system during obesity in mice. This reduces inflammation and hence, decreases pre-diabetes. You cannot just delete genes to fight human disease. Hence, we searched for drugs that can be used to inhibit this immune response. We found that the 2 cancer drugs, Iressa and Tarceva, which are currently being used in humans as a chemotherapy treatment, block the immune pathway we know is important in pre-diabetes. This research is targeted at re-tasking these drugs to reduce the chronic inflammation typically observed during obesity, in order to to combat pre-diabetes. We hope to develop a way to stop Type 2 Diabetes in overweight and obese individuals and reduce costs on the Canadian healthcare system.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Duggan, Brittany
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~